vs
Aclaris Therapeutics, Inc.（ACRS）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
硕腾的季度营收约是Aclaris Therapeutics, Inc.的1843.2倍（$2.4B vs $1.3M）。硕腾净利率更高（25.3% vs -1528.6%，领先1553.8%）。硕腾同比增速更快（3.0% vs -85.9%）。硕腾自由现金流更多（$732.0M vs $-13.2M）。过去两年硕腾的营收复合增速更高（4.4% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
ACRS vs ZTS — 直观对比
营收规模更大
ZTS
是对方的1843.2倍
$1.3M
营收增速更快
ZTS
高出89.0%
-85.9%
净利率更高
ZTS
高出1553.8%
-1528.6%
自由现金流更多
ZTS
多$745.2M
$-13.2M
两年增速更快
ZTS
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $2.4B |
| 净利润 | $-19.8M | $603.0M |
| 毛利率 | 58.9% | 70.2% |
| 营业利润率 | -1755.5% | 31.9% |
| 净利率 | -1528.6% | 25.3% |
| 营收同比 | -85.9% | 3.0% |
| 净利润同比 | 79.5% | 3.8% |
| 每股收益（稀释后） | $-0.16 | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSZTS
| Q4 25 | $1.3M | $2.4B | ||
| Q3 25 | $3.3M | $2.4B | ||
| Q2 25 | $1.8M | $2.5B | ||
| Q1 25 | $1.5M | $2.2B | ||
| Q4 24 | $9.2M | $2.3B | ||
| Q3 24 | $4.3M | $2.4B | ||
| Q2 24 | $2.8M | $2.4B | ||
| Q1 24 | $2.4M | $2.2B |
净利润ACRSZTS
| Q4 25 | $-19.8M | $603.0M | ||
| Q3 25 | $-14.6M | $721.0M | ||
| Q2 25 | $-15.4M | $718.0M | ||
| Q1 25 | $-15.1M | $631.0M | ||
| Q4 24 | $-96.6M | $581.0M | ||
| Q3 24 | $-7.6M | $682.0M | ||
| Q2 24 | $-11.0M | $624.0M | ||
| Q1 24 | $-16.9M | $599.0M |
毛利率ACRSZTS
| Q4 25 | 58.9% | 70.2% | ||
| Q3 25 | 83.7% | 71.5% | ||
| Q2 25 | 71.0% | 73.6% | ||
| Q1 25 | 65.2% | 72.0% | ||
| Q4 24 | 92.3% | 69.5% | ||
| Q3 24 | 85.0% | 70.6% | ||
| Q2 24 | 77.4% | 71.7% | ||
| Q1 24 | 66.3% | 70.6% |
营业利润率ACRSZTS
| Q4 25 | -1755.5% | 31.9% | ||
| Q3 25 | -519.8% | 37.0% | ||
| Q2 25 | -1035.9% | 36.7% | ||
| Q1 25 | -1242.9% | 36.5% | ||
| Q4 24 | -1082.3% | 31.6% | ||
| Q3 24 | -240.9% | 36.6% | ||
| Q2 24 | -464.7% | 33.0% | ||
| Q1 24 | -789.4% | 34.1% |
净利率ACRSZTS
| Q4 25 | -1528.6% | 25.3% | ||
| Q3 25 | -443.0% | 30.0% | ||
| Q2 25 | -868.3% | 29.2% | ||
| Q1 25 | -1036.8% | 28.4% | ||
| Q4 24 | -1048.3% | 25.1% | ||
| Q3 24 | -174.6% | 28.6% | ||
| Q2 24 | -397.2% | 26.4% | ||
| Q1 24 | -706.5% | 27.4% |
每股收益（稀释后）ACRSZTS
| Q4 25 | $-0.16 | $1.37 | ||
| Q3 25 | $-0.12 | $1.63 | ||
| Q2 25 | $-0.13 | $1.61 | ||
| Q1 25 | $-0.12 | $1.41 | ||
| Q4 24 | $-1.21 | $1.29 | ||
| Q3 24 | $-0.11 | $1.50 | ||
| Q2 24 | $-0.15 | $1.37 | ||
| Q1 24 | $-0.24 | $1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.1M | $3.3B |
| 总资产 | $160.5M | $15.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACRSZTS
| Q4 25 | $20.0M | — | ||
| Q3 25 | $25.3M | $2.1B | ||
| Q2 25 | $25.4M | $1.4B | ||
| Q1 25 | $30.4M | $1.7B | ||
| Q4 24 | $24.6M | $2.0B | ||
| Q3 24 | $47.7M | $1.7B | ||
| Q2 24 | $22.8M | $1.6B | ||
| Q1 24 | $35.8M | $2.0B |
股东权益ACRSZTS
| Q4 25 | $103.1M | $3.3B | ||
| Q3 25 | $120.1M | $5.4B | ||
| Q2 25 | $131.7M | $5.0B | ||
| Q1 25 | $144.1M | $4.7B | ||
| Q4 24 | $155.6M | $4.8B | ||
| Q3 24 | $130.2M | $5.2B | ||
| Q2 24 | $133.8M | $5.0B | ||
| Q1 24 | $142.0M | $5.1B |
总资产ACRSZTS
| Q4 25 | $160.5M | $15.5B | ||
| Q3 25 | $175.5M | $15.2B | ||
| Q2 25 | $189.1M | $14.5B | ||
| Q1 25 | $198.1M | $14.1B | ||
| Q4 24 | $220.3M | $14.2B | ||
| Q3 24 | $182.4M | $14.4B | ||
| Q2 24 | $161.1M | $14.2B | ||
| Q1 24 | $174.1M | $14.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | $893.0M |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | $732.0M |
| 自由现金流率自由现金流/营收 | -1015.8% | 30.7% |
| 资本支出强度资本支出/营收 | 1.9% | 6.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $-47.2M | $2.3B |
8季度趋势，按日历期对齐
经营现金流ACRSZTS
| Q4 25 | $-13.1M | $893.0M | ||
| Q3 25 | $-10.9M | $938.0M | ||
| Q2 25 | $-10.0M | $486.0M | ||
| Q1 25 | $-13.1M | $587.0M | ||
| Q4 24 | $-8.9M | $905.0M | ||
| Q3 24 | $22.0M | $951.0M | ||
| Q2 24 | $-12.3M | $502.0M | ||
| Q1 24 | $-20.8M | $595.0M |
自由现金流ACRSZTS
| Q4 25 | $-13.2M | $732.0M | ||
| Q3 25 | $-11.0M | $805.0M | ||
| Q2 25 | $-10.0M | $308.0M | ||
| Q1 25 | $-13.1M | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | $-12.3M | $370.0M | ||
| Q1 24 | $-20.9M | $455.0M |
自由现金流率ACRSZTS
| Q4 25 | -1015.8% | 30.7% | ||
| Q3 25 | -332.1% | 33.5% | ||
| Q2 25 | -563.5% | 12.5% | ||
| Q1 25 | -900.3% | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | -446.0% | 15.7% | ||
| Q1 24 | -873.6% | 20.8% |
资本支出强度ACRSZTS
| Q4 25 | 1.9% | 6.7% | ||
| Q3 25 | 0.7% | 5.5% | ||
| Q2 25 | 1.2% | 7.2% | ||
| Q1 25 | 3.0% | 6.7% | ||
| Q4 24 | 0.0% | 9.3% | ||
| Q3 24 | 0.0% | 7.0% | ||
| Q2 24 | 0.5% | 5.6% | ||
| Q1 24 | 5.6% | 6.4% |
现金转化率ACRSZTS
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRS
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
